Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.655 USD | +2.16% | -0.60% | +8.50% |
Financials (USD)
Sales 2024 * | 24.2M | Sales 2025 * | 83.79M | Capitalization | 586M |
---|---|---|---|---|---|
Net income 2024 * | -200M | Net income 2025 * | -201M | EV / Sales 2024 * | 24.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.99 x |
P/E ratio 2024 * |
-2.12
x | P/E ratio 2025 * |
-2.36
x | Employees | 285 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
1 day | +0.62% | ||
1 week | -8.47% | ||
Current month | +5.19% | ||
1 month | +2.53% | ||
3 months | -38.17% | ||
6 months | +45.95% | ||
Current year | +5.88% |
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +10.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 1.655 | +2.16% | 2 219 733 |
24-05-24 | 1.62 | +0.62% | 2,069,736 |
24-05-23 | 1.61 | -3.59% | 2,281,199 |
24-05-22 | 1.67 | 0.00% | 1,850,463 |
24-05-21 | 1.67 | -5.65% | 4,592,128 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.88% | 586M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.60% | 22.1B | |
-9.14% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- LXRX Stock